BioCryst Pharmaceuticals, Inc.

NASDAQ:BCRX

7.67 (USD) • At close November 7, 2024
Bedrijfsnaam BioCryst Pharmaceuticals, Inc.
Symbool BCRX
Munteenheid USD
Prijs 7.67
Beurswaarde 1,586,815,620
Dividendpercentage 0%
52-weken bereik 4.03 - 8.88
Industrie Biotechnology
Sector Healthcare
CEO Mr. Jon P. Stonehouse
Website https://www.biocryst.com

An error occurred while fetching data.

Over BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing

Vergelijkbare Aandelen

Aurinia Pharmaceuticals Inc. logo

Aurinia Pharmaceuticals Inc.

AUPH

8.34 USD

SpringWorks Therapeutics, Inc. logo

SpringWorks Therapeutics, Inc.

SWTX

33.09 USD

Apollo Medical Holdings, Inc. logo

Apollo Medical Holdings, Inc.

AMEH

40.82 USD

Fulgent Genetics, Inc. logo

Fulgent Genetics, Inc.

FLGT

22.02 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)